Artiva Scraps Lead Candidate AlloNK, Slashes Workforce, Hires Adviser to Explore Options

What happened

Artiva Biotherapeutics ended work on its lead candidate AlloNK, including a planned Phase 3 study, after longer-term data showed clinical response durability fell short of the required threshold. The company is cutting 94% of its workforce, hiring Leerink Partners, and evaluating strategic alternatives such as a merger or liquidation.

Confirmed

Global impact / market context

Stopping the lead program removes Artiva's main path to revenue, leaving a clinical-stage company with no near-term product. That pushes the focus to its roughly $319.1 million in cash and whether a merger, business combination, or liquidation returns more value to shareholders than continued standalone development.

Analyst inference

The 23% premarket drop to $4.72 against a roughly $300 million market value shows investors repricing the company around cash rather than pipeline prospects. Small biotechnology firms with one lead asset often trade on trial durability, so a failed readout can quickly turn the story into a sale or shutdown review.

Analyst inference

What to watch

1. Artiva said it had about $319.1 million in cash, equivalents and investments as of Sept. 30 and hired Leerink Partners to assist its review of strategic alternatives. Confirmed
2. Watch whether the strategic review produces a merger or business combination, a dissolution and liquidation, or another outcome, and what terms are offered to shareholders. Proposed
3. Track remaining staff and spending after the 94% workforce cut, because lower costs slow cash burn and affect how much cash remains for a sale or liquidation payout. Analyst inference

Evidence

• Original source link unavailable